Announcements Trials
Browse Landscape

Status

Completed 6Terminated 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Recurrence 1Neoplasms 1Neoplasm, Residual 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Dexamethasone 87daratumumab 49Lenalidomide 49pomalidomide 33Bortezomib 32Cyclophosphamide 31carfilzomib 25Calcium Dobesilate 21talquetamab 19fludarabine 18isatuximab 16iberdomide 16Magnetic Resonance Spectroscopy 16Specimen Handling 15Biopsy 14selinexor 12Melphalan 11belantamab mafodotin 10dexamethasone acetate 9dexamethasone 21-phosphate 8elotuzumab 7auricularum 7venetoclax 6tocilizumab 5fludarabine phosphate 5X-Rays 5Blood Specimen Collection 5ruxolitinib 4Methylprednisolone 4Injections 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Multiple Myeloma × Transplantation, Autologous × Clear all
NCT06463717 2024-06-24

Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not

First Affiliated Hospital of Zhejiang University

Recruiting
210 enrolled
Plasma cell

Multiple Myeloma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡